NET revenue ramp slows, Exelixis drug is under FDA review, and Ipsen receives royalties from cabozantinib sales.
3 reports, 2 independent
Updated Sep 15
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NET revenue ramp slows, Exelixis drug is under FDA review, and Ipsen receives royalties from cabozantinib sales.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA sets PDUFA date for drug review, while Ipsen confirms its role in franchise revenue.1 source
Exelixis faces revenue slowdown while Ipsen collects royalties and another drug is under FDA review.1 source